Application of Cis-Diamminedichloro-Platinum in Combination Antineoplastic Therapy of Testicular Cancer

1978 ◽  
Vol 12 (4) ◽  
pp. 226-229 ◽  
Author(s):  
Janice M. Williams ◽  
Nicholas G. Popovich
Keyword(s):  
Adverse Effects ◽  
Testicular Cancer ◽  
Antineoplastic Therapy ◽  
Mechanism Of Action ◽  
Combination Chemotherapy ◽  
Clinical Use ◽  
Adult Males ◽  
Testicular Carcinoma ◽  
Dosage Administration

Testicular carcinoma is a leading cause of cancer-related deaths in adult males between the ages of 20 and 35. Cis-Diamminedichloroplatinum (II) (i.e., CDDP) is currently being used investigatively in combination chemotherapy for the treatment of this disease. This article reviews the literature to date on CDDP and its application in testicular cancer. Individual CDDP parameters (e.g., chemistry, mechanism of action, effectiveness and clinical use, adverse effects, dosage, administration and distribution) are discussed.

Local anaesthetics: Theoretical aspects

2021 ◽  
pp. 175573802110351
Author(s):  
Gareth Allen ◽  
Rebecca Butler
Keyword(s):  
Primary Care ◽  
Adverse Effects ◽  
Surgical Procedures ◽  
Local Anaesthetic ◽  
Secondary Care ◽  
Local Anaesthetics ◽  
Clinical Use ◽  
Minor Surgical Procedures ◽  
Nervous Conduction

Local anaesthetics are frequently used in both primary and secondary care. These agents transiently reduce the nervous conduction of nociceptive signals, reducing sensations of pain. In primary care, local anaesthetics are often used for minor surgical procedures. However, there are other uses for these agents. It is important to understand the issues encountered when using local anaesthetics in primary care. This review will cover clinical use, relevant pharmacology and adverse effects of the different local anaesthetic preparations.

Ecotoxicity Effects of Nanomaterials on Aquatic Organisms

2016 ◽  
pp. 330-351 ◽  
Author(s):  
César A Barbero ◽  
Edith Inés Yslas
Keyword(s):  
Adverse Effects ◽  
Surface Charge ◽  
Direct Effect ◽  
Mechanism Of Action ◽  
Aquatic Environment ◽  
Physicochemical Characteristic ◽  
Aquatic Organisms ◽  
Development Stage ◽  
Engineered Nanomaterials ◽  
Toxicity Data

The increasing production and use of engineered nanomaterials raise concerns about inadvertent exposure and the potential for adverse effects on the aquatic environment. The aim of this chapter is focused on studies of nanotoxicity in different models of aquatic organisms and their impact. Moreover, the chapter provides an overview of nanoparticles, their applications, and the potential nanoparticle-induced toxicity in aquatic organisms. The topics discussed in this chapter are the physicochemical characteristic of nanomaterials (size, aggregation, morphology, surface charge, reactivity, dissolution, etc.) and their influence on toxicity. Further, the text discusses the direct effect of nanomaterials on development stage (embryonic and adult) in aquatic organisms, the mechanism of action as well as the toxicity data of nanomaterials in different species.f action as well as the toxicity data of nanomaterials in different species.

Mineralocorticoid receptor antagonists

ESC CardioMed ◽  
2018 ◽  
pp. 167-173
Author(s):  
Faiez Zannad ◽  
João Pedro Ferreira
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Adverse Effects ◽  
Beneficial Effect ◽  
Mechanism Of Action ◽  
Mineralocorticoid Receptor ◽  
Post Myocardial Infarction ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Clinical Syndromes

Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines while recommending a MRA do not make a clear recommendation as to which MRA should be used, how doses should be titrated, or which monitorization is indicated. This chapter provides an appraisal of the different types of MRA drugs and their pharmacological differences with respect to mechanism of action, pharmacokinetics, monitoring, adverse effects, and drug interactions.

Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer.

1990 ◽  
Vol 8 (1) ◽  
pp. 21-26 ◽  
Author(s):  
M Boyer ◽  
D Raghavan ◽  
P J Harris ◽  
J Lietch ◽  
A Bleasel ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Combination Chemotherapy ◽  
Late Toxicity ◽  
Smoking History ◽  
Diffusing Capacity ◽  
Peripheral Nerve Damage ◽  
Single Breath ◽  
Advanced Testicular Cancer

To date, the prevalence and nature of the late toxicity of cisplatin-based combination chemotherapy for advanced testicular cancer has been poorly documented. Thirty men with a median age of 35 years (range, 23 to 63), who had undergone such treatment were assessed with detailed investigation to determine the type and frequency of chronic toxicity. The median follow-up from the time of commencement of chemotherapy was 75 months (range, 48 to 126). The most common late toxic effects were high tone hearing loss in 23 men (77%) and electrophysiological evidence of peripheral nerve damage in 15 (50%). Both the hearing and nerve abnormalities were predominantly asymptomatic. In addition, elevation of serum cholesterol, noted in 20 patients (67%), was significant (P = .014) when compared with a control population. Hyperuricemia was present in nine patients (30%). Only one patient, with other risk factors (smoking, family history), had evidence of ischaemic heart disease while 20% (all with a smoking history) had a diminished single breath diffusing capacity for carbon monoxide (DLCO). Cisplatin-based chemotherapy is relatively free of major long-term side effects and should not be withheld for fear of late toxicity.

Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects

Life Sciences ◽  
2020 ◽  
Vol 256 ◽  
pp. 117984 ◽  
Author(s):  
Milad Ashrafizadeh ◽  
Ali Zarrabi ◽  
Farid Hashemi ◽  
Ebrahim Rahmani Moghadam ◽  
Fardin Hashemi ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Adverse Effects ◽  
Combination Chemotherapy

scholarly journals Mechanism of Action of Icariin in Bone Marrow Mesenchymal Stem Cells

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Aofei Yang ◽  
Chaochao Yu ◽  
Qilin Lu ◽  
Hao Li ◽  
Zhanghua Li ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Mechanism Of Action ◽  
Underlying Mechanism ◽  
Bone Defects ◽  
Clinical Use ◽  
Regenerative Therapy ◽  
Herba Epimedii ◽  
Marrow Mesenchymal Stem Cells

Osteoporosis, femoral head necrosis, and congenital bone defects are orthopedic disorders characterized by reduced bone generation and insufficient bone mass. Bone regenerative therapy primarily relies on the bone marrow mesenchymal stem cells (BMSCs) and their ability to differentiate osteogenically. Icariin (ICA) is the active ingredient of Herba epimedii, a common herb used in traditional Chinese medicine (TCM) formulations, and can effectively enhance BMSC proliferation and osteogenesis. However, the underlying mechanism of ICA action in BMSCs is not completely clear. In this review, we provide an overview of the studies on the role and mechanism of action of ICA in BMSCs, to provide greater insights into its potential clinical use in bone regeneration.

Early-onset thrombocytopenia during combination chemotherapy in testicular cancer is induced by vinblastine

Cancer ◽  
1989 ◽  
Vol 63 (1) ◽  
pp. 51-58 ◽  
Author(s):  
Günter Steurer ◽  
Rudolf Kuzmits ◽  
Margit Pavelka ◽  
Helmut Sinzinger ◽  
Elke Fritz ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Combination Chemotherapy ◽  
Early Onset
Sign in / Sign up

Export Citation Format

Share Document